Please login to the form below

Not currently logged in
Email:
Password:

Organogenesis

This page shows the latest Organogenesis news and features for those working in and with pharma, biotech and healthcare.

Shire pays record $350m to settle US kickback allegations

Shire pays record $350m to settle US kickback allegations

Dermagraft has proved to be something of an expensive debacle for Shire, which took a $650m charge when it offloaded the product to Organogenesis, a decision prompted by its failure to

Latest news

  • Shire faces $650m loss on Dermagraft sale Shire faces $650m loss on Dermagraft sale

    Organogenesis now owns the rights to all Dermagraft assets, including patents, product inventory and certain manufacturing equipment. ... Shire will receive no upfront payment from Organogenesis, although it is entitled to receive up to $300m in

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    320. Shire/ Organogenesis. Divestment. Shire's sale of its Dermagraft assets acquired as part of Advanced BioHealing.

  • Pharma deals during January 2014 Pharma deals during January 2014

    The Merck &Co divestment of Sirna is noted above but, this month, Shire announced the divestment of Dermagraft (a bioengineered skin substitution product for diabetic foot ulcers) to Organogenesis.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Vifor Pharma appoints Dario Eklund Vifor Pharma appoints Dario Eklund

    Eklund joins from Organogenesis, a regenerative medicine company which focuses in wound healing and soft tissue regeneration, where he was VP with responsibility for non-US operations, business development and licensing

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics